Business
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update
PUR1800 Phase 1b study is fully enrolled with data anticipated in Q1 2022 PUR1800 6-month rat and 9-month dog toxicology data may enable expansion to chronic
About this update from Pulmatrix, Inc.
[{"type":"text","content":"PUR1800 Phase 1b study is fully enrolled with data anticipated in Q1 2022\n PUR1800 6-month rat and 9-month dog toxicology data may enable expansion to chronic conditions\n PUR3100 Phase 1/ Phase 2 clinical study in acute migraine treatment on-track for start in Q1 2022\n Projected cash runway extends beyond PUR1800 Phase 1b Q1 2022 and PUR3100 Phase 1 / Phase 2 Q4 2022 data milestones\n\n\nLEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its second quarter 2021 financial results and provides a business update.\n\n \n \n \n \n \n \n\n \n\"We have made steady progress across our pipeline in the second quarter,\" said Ted Raad, Chief Executive Officer of Pulmatrix. \"Recent toxicology data from PUR1800 suggests the potential to expand into indications that require chronic dosing. We look forward to presenting topline data from the fully enrolled, ongoing Phase 1b study of PUR1800 in Q1 2022. We are also rapidly advancing towards the clinic with PUR3100 in acute migraine. We believe that our strong cash position allows us to advance our pipeline through major data milestones into 2023.\" \nSecond Quarter and Recent Highlights:\nPUR1800\nCompleted enrollment in ongoing Phase 1b clinical study of PUR1800 in acute exacerbations in COPD (AECOPD). Study endpoints include safety, tolerability, and exploratory biomarkers to demonstrate target engagement and anti-inflammatory effect. PUR1800 Phase 1b top-line data is expected in Q1 2022. Results from 6-month rat and 9-month dog toxicology results demonstrate no progression of 28-day findings, suggesting potential for chronic dosing of PUR1800 in indications beyond AECOPD including, but not limited to, steroid resistant asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company estimates an approximate peak net revenue opportunity of $2.4B in AECOPD1, due to the significant unmet need beyond standard of care oral steroids and/or antibiotic therapy. Expansion to chronic indications should further broaden the market potential of PUR1800.PUR3100\n14-day toxicology results for PUR3100, Pulmatrix's dry powder iSPERSE formulation o...